Autolus Therapeutics plc
AUTL
$2.12
-$0.11-4.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 26.22M | 24.29M | 21.19M | 20.92M | 8.98M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.22M | 24.29M | 21.19M | 20.92M | 8.98M |
| Cost of Revenue | 45.78M | 54.29M | 56.54M | 25.97M | 44.69M |
| Gross Profit | -19.56M | -30.00M | -35.34M | -5.05M | -35.70M |
| SG&A Expenses | 39.95M | 42.12M | 36.28M | 30.27M | 29.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.73M | 96.41M | 92.82M | 82.14M | 74.22M |
| Operating Income | -59.51M | -72.12M | -71.62M | -61.22M | -65.24M |
| Income Before Tax | -70.74M | -91.52M | -78.59M | -47.52M | -67.94M |
| Income Tax Expenses | 863.00K | -1.18M | 532.00K | 397.00K | 2.23M |
| Earnings from Continuing Operations | -71.60M | -90.33M | -79.12M | -47.92M | -70.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.60M | -90.33M | -79.12M | -47.92M | -70.16M |
| EBIT | -59.51M | -72.12M | -71.62M | -61.22M | -65.24M |
| EBITDA | -56.81M | -69.49M | -69.08M | -58.85M | -62.96M |
| EPS Basic | -0.27 | -0.34 | -0.30 | -0.18 | -0.26 |
| Normalized Basic EPS | -0.17 | -0.21 | -0.18 | -0.11 | -0.16 |
| EPS Diluted | -0.27 | -0.34 | -0.30 | -0.18 | -0.26 |
| Normalized Diluted EPS | -0.17 | -0.21 | -0.18 | -0.11 | -0.16 |
| Average Basic Shares Outstanding | 266.14M | 266.14M | 266.14M | 266.14M | 266.13M |
| Average Diluted Shares Outstanding | 266.14M | 266.14M | 266.14M | 266.14M | 266.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |